JRCT ID: jRCT2031220197
Registered date:08/07/2022
Substudy 06A: Phase 1/2 Umbrella Study of Combination Therapies in Esophageal Cancer
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Esophageal Squamous Cell Carcinoma (ESCC) |
Date of first enrollment | 27/07/2022 |
Target sample size | 12 |
Countries of recruitment | France,Japan,Italy,Japan,Singapore,Japan,South Korea,Japan,Taiwan,Japan,Thailand,Japan,Turkey,Japan,Brazil,Japan,Chile,Japan,Norway,Japan,Switzerland,Japan,Germany,Japan |
Study type | Interventional |
Intervention(s) | - Pembrolizumab plus chemotherapy Participants will receive pembrolizumab intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years. - Coformulation Favezelimab/Pembrolizumab plus Chemotherapy Participants will receive coformulation of favezelimab/pembrolizumab administered intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years. - Pembrolizumab plus MK-4380 plus Chemotherapy Participants will receive pembrolizumab intravenously plus MK-4380 plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years. - Pembrolizumab plus MK-4380 plus lenvatinib Participants will receive pembrolizumab intravenously plus MK-4380 plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years. - Pembrolizumab: 200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W) - Irinotecan: 180 mg/m^2 administered via IV infusion on day 1 of every 14-day cycle. - Paclitaxel: 80-100 mg/m^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle - Coformulation favezelimab/pembrolizumab: 800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W - MK-4830: 800 mg administered via IV infusion Q3W - Lenvatinib: 20 mg administered via oral capsules each day |
Outcome(s)
Primary Outcome | - Number of Participants Experiencing a Dose-limiting Toxicity (DLT) During Safety Lead-in Phase - Number of Participants Experiencing an Adverse Event (AE) During Safety Lead-in Phase - Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in Phase - Objective Response Rate (ORR) |
---|---|
Secondary Outcome | - Progression-Free Survival (PFS) - Duration of Response (DOR) - Overall Survival (OS) - Number of Participants Experiencing at Least One Adverse Event (AE) During the Efficacy Phase - Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | - Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable ESCC. - Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy. - Has an evaluable baseline tumor sample (newly obtained or archival) for analysis - Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to =<Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have =<Grade 2 neuropathy are eligible |
Exclude criteria | - Direct invasion into adjacent organs such as the aorta or trachea. - Has experienced weight loss >10% over approximately 2 months prior to first dose of study therapy. - Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration. - Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication. - Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy. - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. - Active autoimmune disease that has required systemic treatment in past 2 years - History of human immunodeficiency virus (HIV) infection - History of Hepatitis B or known active Hepatitis C virus infection. - History of allogenic tissue/solid organ transplant. - Clinically significant cardiovascular disease within 12 months from first dose of study intervention. - Has risk for significant GI bleeding, such as: * Has had a serious nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization |
Related Information
Primary Sponsor | Koh Yasuhiro |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT05342636 |
Contact
Public contact | |
Name | inquiry mailbox MSDJRCT |
Address | KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan Tokyo Japan 102-8667 |
Telephone | +81-3-6272-1957 |
msdjrct@merck.com | |
Affiliation | MSD K.K. |
Scientific contact | |
Name | Yasuhiro Koh |
Address | KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan Tokyo Japan 102-8667 |
Telephone | +81-3-6272-1957 |
msdjrct@merck.com | |
Affiliation | MSD K.K. |